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Abstract
Airway remodeling is not specifically targeted by current asthma medications, partly owing to the lack of
understanding of remodeling mechanisms, altogether posing great challenges in asthma treatment. Increased
airway smooth muscle (ASM) mass due to hyperplasia/hypertrophy contributes significantly to overall airway
remodeling and correlates with decline in lung function. Recent evidence suggests that IgE sensitization can
enhance the survival and mediator release in inflammatory cells. Human ASM (HASM) cells express both low affinity
(FcεRII/CD23) and high affinity IgE Fc receptors (FcεRI), and IgE can modulate the contractile and synthetic function
of HASM cells. IgE was recently shown to induce HASM cell proliferation but the detailed mechanisms remain
unknown. We report here that IgE sensitization induces HASM cell proliferation, as measured by
3H-thymidine, EdU
incorporation, and manual cell counting. As an upstream signature component of FcεRI signaling, inhibition of
spleen tyrosine kinase (Syk) abrogated the IgE-induced HASM proliferation. Further analysis of IgE-induced signaling
depicted an IgE-mediated activation of Erk 1/2, p38, JNK MAPK, and Akt kinases. Lastly, lentiviral-shRNA-mediated
STAT3 silencing completely abolished the IgE-mediated HASM cell proliferation. Collectively, our data provide
mechanisms of a novel function of IgE which may contribute, at least in part, to airway remodeling observed in
allergic asthma by directly inducing HASM cell proliferation.
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Introduction
Nearly 80% of children and more than 50% of adult
asthma is thought to be allergic/immunoglobulin E (IgE)-
dependent [1]. Classical dogma defines the allergic reac-
tion in two steps; first when antigen-specific IgE binds to
its high affinity Fc receptor (FcεRI) on mast cells and ba-
sophils (sensitization step). Next, antigen/allergen binding
to specific IgE ‘cross-links’ the FcεRI which culminates in
various cell activation events such as degranulation, de
novo synthesis and secretion of inflammatory mediators,
and promotion of cell survival and migration [2]. How-
ever, recent studies have established a new paradigm in
which IgE sensitization alone can induce a spectrum of
effects such as the release of proinflammatory cytokines
and chemokines, inhibition of apoptosis or induction of
pro-survival effects through activation of various signaling
pathways. So far, monomeric IgE has been shown to en-
hance the survival of mast cells, monocytes, and asthmatic
neutrophils [2,3].
Airway smooth muscle (ASM) cells are structural entities
of airways which are believed to confer an abnormally ex-
aggerated bronchoconstriction in asthma, the phenomenon
commonly known as airway hyperresponsiveness (AHR).
Clinically, majority of asthma patients show a significant
increase in ASM bundles, likely due to increase in cell
number, collectively contributing to airway remodeling [4].
Tissue remodeling due to increased ASM mass in allergic
asthma is also known to correlate with AHR in some pa-
tients [5]. Although precise mechanisms remain yet to be
established, an increase in cell number (hyperplasia) is sug-
gested to be one of the primary factors underlying this in-
crease in ASM mass [4,6]. Molecular studies suggest that
mitogen activated protein kinases (MAPK) family and sig-
nal transducer and activator of transcription (STAT) 3, be-
sides other pathways, play pivotal role in regulating ASM
cell proliferation under various contexts [7,8].
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smooth muscle function. Bronchial hyperresponsiveness
was shown to be associated with serum IgE levels [9]. IgE
was also shown to cause smooth muscle contractile func-
tion through binding to the smooth muscle membrane and
subsequent hyperpolarization [10]. We and others have
demonstrated previously that human ASM (HASM) cells
express a functional tetrameric high affinity FcεRI (αβγ2).
IgE/anti-IgE stimulation of HASM induced the release of
Th2 and proinflammatory mediators IL-4, -5, -13, TNF,
IL-6, CCL11/eotaxin-1, and thymic stromal lymphopoietin
(TSLP), and enhanced intracellular calcium ([Ca
2+]i)
mobilization [11,12]. Cumulative evidence has established
a critical role of IgE/FcεR interaction in modulation of
HASM function and phenotype [12-15]. Although IgE-
induced ASM proliferation was reported recently [16], the
molecular mechanisms remain unknown. We show here
that IgE induces proliferation of ASM cells via MAPK,
Akt, and STAT3 signaling pathways; suggesting that IgE
may indeed contribute, at least partly, to the development
of airway remodeling in allergic asthma.
Materials and methods
Reagents
Recombinant human IgE was obtained from Diatec
(BioPorto Diagnostics A/S, Denmark). Fetal bovine serum
(FBS), sodium pyruvate, trypsin were purchased from
HyClone (Logan, UT, USA). 100× L-glutamine, DMEM,
Ham’s F-12, trypsin-EDTA, and antibiotics (penicillin,
streptomycin) were purchased from Invitrogen Canada Inc.
(Burlington, ON, Canada). Platelet-derived growth factor-
BB (PDGF-BB) was from R&D Systems, Minneapolis, MN,
USA). Rabbit anti-human p38 MAPK mAb, affinity-
purified mouse anti-phospho-ERK1/2 (T202/Y204), rabbit
anti-human ERK1/2 mAb, affinity-purified rabbit anti-
phospho-p38 MAPK (T180/Y182), rabbit anti-total and
phospho-specific SAPK/JNK (T183/Y185) Abs, rabbit
mAb phospho-Akt (Ser 473) and total-Akt antibody were
purchased from Cell Signaling Technology, Inc (Danvers,
MA). Mouse mAb anti-phospho-tyrosine STAT3 (Y705)
was from BD Biosciences (Mississauga, ON). Affinity puri-
fied rabbit anti-total STAT3 antibody and rabbit polyclonal
anti-Syk (C-20) antibody were from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA). The p38 MAPK inhibitor, SB-
203580; JNK inhibitor, SP-600125; p42/p44 ERK inhibitor,
U-0126; and cell-permeable Akt inhibitor VII, TAT-Akt-in
were purchased from CALBIOCHEM® (EMD Millipore),
San Diego, CA, USA. Unless stated otherwise, all other re-
agents were obtained from Sigma-Aldrich Canada Ltd.
(Oakville, ON, Canada).
Culture and stimulation of HASM cells
HASM cells were prepared and maintained as we have
reported earlier [11,17,18]. Written informed consent
was obtained from the tissue donors, and this study was
approved by the research ethics committee of the Uni-
versity of Manitoba, Winnipeg, Canada. In all experi-
ments, sub-confluent HASM cells were growth arrested
and synchronized by serum deprivation for 48 h in Ham’s
F-12 medium containing 1× ITS (5 μg/ml human recom-
binant insulin, 5 μg/ml human transferrin, 5 ng/ml selen-
ium), and antibiotics (100 U/ml penicillin and 100 μg/ml
streptomycin). Cells were then stimulated in fresh FBS-
free medium with agonists for indicated time periods.
Manual cell counting and
3H-thymidine incorporation to
measure HASM cell proliferation
HASM cell proliferation was measured by manual cell
counting. Tritiated (
3H)-thymidine incorporation assay
was performed to measure DNA synthesis as a surrogate
marker of cell proliferation by following the method of
Goncharova and colleagues [19] with minor modifica-
tions. Briefly, ASM cells were seeded in 24-well tissue
culture plates (3 ×10
4 cells/well) to grow to about 70%
confluency in a 37°C humidified 5% CO2 incubator. Cells
were serum-deprived in Ham’s F12 containing 1× ITS
media for 48 h to growth-arrest and synchronize them.
Fresh F12 containing 1× ITS was added and cells were
stimulated with graded doses of IgE and other mitogens
for 16 h. 10% FBS or PDGF-BB (10 ng/ml) was used (fol-
lowing dose titration) as a positive control. After 16 h,
methyl-
3H-thymidine (Specific activity 20 Ci [740 GBq]/
mMole, >97%; Perkin Elmer, Woodbridge, ON, Canada)
was added at a final concentration of 2 μCi/ml and cells
were incubated at 37°C for 24 h. Subsequently, ASM
cells were rinsed in PBS three times before adding 0.1 ml
0.05% trypsin-EDTA for 15 minutes at 37°C for lysis,
followed by addition of 0.1 ml ice-cold 20% trichloroacetic
acid (TCA) for 20 minutes at 4°C to precipitate the DNA.
Precipitated DNA was then carefully transferred to 96-well
plates to facilitate its absorption on 96-well format glass
fibre filter mats (Wallac, Turku, Finland) using Tomtec
Harvestor 96 (Tomtec Inc., Hamden, CT, USA). Filter mats
were air-dried and counted in liquid scintillation counter.
In some experiments, MAPK inhibitors were used for one
hour prior to IgE stimulation. Experiments were performed
in triplicate and the data was presented as mean±SEM of
counts per minute (cpm).
EdU-incorporation assay for HASM cell proliferation
HASM cell proliferation was additionally measured by
using Click-it EdU Proliferation kit (Invitrogen) by
following the manufacturer’s instructions. Briefly, sub-
confluent 48 h serum-starved ASM cells were stimu-
lated with graded doses of IgE (5-25 μg/ml) and PDGF
(10 ng/ml) for 16 h following which cells were allowed
to incorporate EdU (5-ethynyl-2′-deoxyuridine; 5 μM)
for 24 h and then trypsinized and fixed. Fixed cells were
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detection reagent conjugated with Alexa Fluor 488, and
cell nuclei were stained with DAPI. EdU-positive cells were
visualized by using flow cytometry and are presented as %
proliferating population on right side of the histogram.
Western blotting to assess MAPK and STAT3
phosphorylation
IgE-induced ASM signaling pathways were studied by
performing Western blotting for phosphorylated MAPK
and STAT3, as described earlier [20]. Intensity of phos-
phorylation was assessed by performing densitometry
analysis using AlphaEaseFC (FluorChem 8800) Software.
The data was presented as fold increase in the ratio of
phospho and total compared to time zero.
Lentivirus-mediated STAT3-shRNA transduction in HASM
cells
Lentiviral transduction of Syk-short hairpin (sh) RNA
(clone ID: V2LHS_153702) and STAT3-short hairpin (sh)
RNA (clone ID: V2LHS_262105) in HASM cells was
performed as described earlier [21]. Mock and lentiviral-
Syk- or lentiviral-STAT3-shRNA-transduced HASM cells
were cultured in presence of IgE (10 μg/ml), PDGF-BB
(10 ng/ml), FBS (10%), or medium alone; and cell prolifer-
ation was assessed by
3H-thymidine incorporation assay.
Figure 1 IgE induces DNA synthesis and cell proliferation in HASM cells. (A) Serum-starved HASM cells were stimulated with IgE (5–25 μg/
ml), PDGF-BB (10 ng/ml), or left unstimulated.
3H-thymidine incorporation was measured by liquid scintillation counting and presented as cpm.
(B) IgE or PDGF-BB-stimulated cells were trypsinized after 48 h and counted by hemocytometer. (C) HASM cells stimulated similar to (A) were
subjected to EdU-incorporation assay. EdU positive cell populations from a representative experiment are shown. n=3; *p <0.05, ***p<0.001
compared to unstimulated control.
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Statistical analysis was performed by using GraphPad
Prism Software Version 3.02 for Windows (GraphPad
Software, San Diego, CA, USA). Data between groups was
compared by using student’su n p a i r e dt test. P values <0.05
were considered statistically significant.
Results
IgE induces DNA synthesis and proliferation in HASM cells
To test the mitogenic potential of IgE on human ASM cells,
we performed
3H-thymidine incorporation assay. While IgE
did not affect cell survival (data not shown); as shown in
Figure 1A, IgE induced de novo DNA synthesis in HASM
cells (n= 5, p < 0.05). As expected, PDGF induced promin-
ent increase in DNA synthesis and served as positive
control [8,18]. We further validated the IgE-induced
3H-
thymidine incorporation data by using hemocytometer-
based cell counting. IgE-induced thymidine incorporation
appeared to have translated into increase in cell number
c o m p a r e dt oc o n t r o l( F i g u r e1 B ,n=4 ,p<0 . 0 5 ) ,s u g g e s t i n g
that IgE is able to induce DNA synthesis and subsequent
proliferation in HASM cells (Figure 1A, B).
In addition, we confirmed the proliferative effect of IgE
on HASM cells by using EdU incorporation. As shown in
Figure 1C, IgE clearly induced HASM cell proliferation, in
almost similar manner to
3H-thymidine incorporation and
manual cell counting (Figure 1). Therefore, our data sug-
gest that IgE can induce HASM cell proliferation.
Lentivirus-mediated Syk inhibition abrogates IgE-induced
HASM proliferation
FcεRI activation leads to a spectrum of signaling events
in inflammatory cells, starting with phosphorylation of
Lyn kinase followed by recruitment and phosphorylation
of Syk. Activation of Syk then serves as an indispensable
mechanism of downstream propagation of signals lead-
ing to the activation of various kinases, transcription
factors, mediator release, and survival [2,22,23]. This
suggests that inhibition/silencing of Syk might be a use-
ful strategy to validate the role of Syk and FcεRI pathway
in IgE-induced HASM cell proliferation. To test this, we
utilized the lentiviral-mediated Syk inhibition strategy,
which we have reported earlier in IgE-induced mediator
release in HASM cells [15,17]. HASM cells were stably
transduced with pseudotyped lentiviral vector expressing
specific Syk-shRNA. Mock and scramble sequence were
used as negative controls. As reported earlier [15,17],
more than 95% of HASM cells were transduced by turbo-
GFP signal positivity by FACS analysis (data not shown).
Lentiviral-Syk-shRNA but not control scramble-shRNA
transduction resulted in a highly significant and reprodu-
cible decrease in Syk expression, as shown by Western
blotting (Figure 2A). We then used these lentiviral-
transduced cells and stimulated them with IgE and PDGF.
As shown in Figure 2B, scramble-shRNA-transduced
HASM cells demonstrated a significant increase in thymi-
dine incorporation (p<0.05, n=3) similar to the wild-
type cells (Figure 1A). However, Syk-shRNA-transduced
cells lost the effect of IgE (p>0.05, non-significant). PDGF
consistently showed highly significant (p<0.001) thymi-
dine incorporation in both scramble and Syk-inhibited
HASM cells (Figure 2B). These results suggest that IgE-
induced proliferation requires the function of Syk, a key
signaling pathway in FcεRI activation.
IgE activates multiple signaling pathways in HASM cells
To understand the downstream molecular signaling path-
ways involved in IgE-induced HASM cell proliferation, we
assessed the phosphorylation of MAPK and Akt by
performing Western blot analysis on HASM cell lysates
stimulated with IgE for 0–120 min. Western blotting re-
vealed a significant JNK phosphorylation at 20–30 min,
Erk1/2 at 60 min, p38 at 120 min, and Akt at 60 min
( n = 3 ,F i g u r e3 A ,B ) .I ns u m m a r y ,I g Ep h o s p h o r y l a t e s
MAPK and Akt kinases in HASM cells which may play
a role in IgE-induced cell proliferation.
Figure 2 IgE-induced HASM cell proliferation requires Syk
activity. (A) HASM cells were stably transduced with pseudotyped
lentiviral vectors expressing Syk-shRNA or non-specific scramble-
shRNA. Syk expression was assessed by Western blotting as
described in Material and Methods section. (B) Syk- or scramble-
shRNA-transduced HASM cells were stimulated with IgE (10 μg/ml),
PDGF-BB (10 ng/ml), or left unstimulated. 3H-thymidine
incorporation was measured as a marker of cell proliferation as in
Figure 1A. n=3, *p< 0.05, ***p<0.001, and ns, non-significant
compared to unstimulated control.
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proliferation
We then confirmed the involvement of different MAPKs
in IgE-induced HASM cell proliferation by using specific
MAPK inhibitors. The dose of various inhibitors was
first optimized to find the dose that inhibits IgE-
induced cell proliferation without inducing a noticeable
cytotoxicity (data not shown). Figure 4 shows that IgE-
induced HASM cell proliferation was inhibited signifi-
cantly (p<0.05, n=3) upon pre-incubation for one hour
with inhibitors of Erk1/2 (1 μM, U0126), JNK (10 nM,
SP600125), p38 (10 μM, SB203580), and Akt (10 μM,
TAT-Akt-in). DMSO vehicle control did not show any ef-
fect on HASM cell proliferation (data not shown). In con-
clusion, IgE-induced HASM cell proliferation involves the
activation of Erk1/2, p38, JNK MAPK, and Akt kinases.
STAT3 is critical in IgE-induced HASM cell proliferation
STAT3 activation is indispensable in HASM cell prolifer-
ation in response to PDGF [8]. Interestingly, monomeric
IgE induces STAT3 phosphorylation in murine bone
marrow-derived mast cells and rat basophilic leukemia
cells, and induce the transcription of genes important in
cell survival [24]. With these reports in consideration,
we first sought to determine whether IgE is able to phos-
phorylate STAT3 in HASM cells. A representative blot
in Figure 5A and summary of 4 experiments in Figure 5B
show that IgE indeed induced STAT3 phosphorylation
in HASM cells. To confirm its role in HASM cell
proliferation, we employed lentiviral vector-mediated
STAT3 silencing approach [20]. HASM cells were stably
transduced with pseudotyped lentiviral vector encoding
specific STAT3-shRNA. Mock and scramble sequence
served as controls. More than 95% of HASM cells were
transduced as observed by turbo-GFP signal by FACS
analysis (data not shown). Lentiviral-STAT3-shRNA
transduction resulted in a noticeable decrease in STAT3
expression compared to WT or scramble-shRNA trans-
duction controls (Figure 5C) [21]. Both scramble-
shRNA- and STAT3-shRNA-transduced HASM cells
were stimulated with IgE and PDGF to analyze thymi-
dine incorporation. Since PDGF-induced mitogenic sig-
naling requires STAT3 expression [8], 10% FBS was
used as an additional positive control in this experi-
ment. As expected, scramble-shRNA-transduced HASM
cells showed a normal and statistically significant re-
sponse to IgE (p <0.05), PDGF, and 10% FBS (p < 0.001)
compared with unstimulated control (Figure 5D). How-
ever, the effect of IgE was completely abrogated in
STAT3-shRNA transduced cells, and so was the effect
of PDGF, also confirming the previous reports [8]. On
the other hand, although 10% FBS showed increased
thymidine incorporation in STAT3-shRNA-transduced
cells, the effect was much less pronounced when com-
pared with scramble-shRNA-transduced HASM cells
(Figure 5D). This is consistent with the observation by
other groups [8], and suggests that the serum compo-
nents may also require STAT3 activation to induce
Figure 3 IgE induces MAPK and Akt phosphorylation in HASM cells. (A) Phosphorylation of MAPKs (ERK1/2, p38, and JNK) and Akt were
assessed by immunoblotting from total cell lysates of IgE-stimulated HASM cells as described in Materials and Methods section.
(B) Phosphorylation intensity was measured be densitometry analysis and expressed as fold increase over time zero of the ratio of phospho
over total levels (n=3).
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data suggest that IgE-induced STAT3 activation plays a
critical role in HASM cell proliferation.
Discussion
We report in this study that IgE sensitization induces
DNA synthesis and proliferation in HASM cells through
the activation of Syk, and signaling Erk 1/2, p38, JNK
MAPK, and Akt kinases. Lentivirus-shRNA-mediated
experiments showed that STAT3 activation is indispens-
able for IgE-induced HASM cell proliferation. Collect-
ively, we show for the first time that IgE sensitization
can directly induce human ASM cell proliferation which
may contribute, at least partly, to the airway remodeling
in allergic asthma.
Serum IgE levels were shown to affect ASM cell function
and tend to correlate with AHR [9]. Cumulative data in last
decade has defined a direct role of IgE in ASM cell activa-
tion. We and others have shown that FcεRI activation by
IgE/anti-IgE incubation leads to enhanced release of pro-
asthmatic cytokines (IL-4, -5, -13, TNF, IL-6, and TSLP),
eosinophil-attracting CCL11/eotaxin-1 chemokine; and a
rapid and transient increase in ([Ca
2+]i) mobilization,
altogether suggesting a critical role of this pathway in air-
way inflammation and hyperresponsiveness [11,12,14,15].
Importantly, blocking of FcεRI led to abrogation of IgE-
induced HASM cell synthetic functions [11]. Moreover,
TNF and IL-4 can augment FcεRI expression and amplify
IgE-induced release of chemokines including CCL11/
eotaxin-1, CCL5/RANTES, CXCL8/IL-8, and CXCL10/IP-
10 [17]. Although Xia et al. were unable to demonstrate
the expression of FcεRI in ASM cells [25], possible expla-
nations for this discrepancy were discussed recently [26].
Furthermore, other groups have shown that IgE/anti-IgE
treatment of HASM cells induce modest levels of matrix
metalloprotease 1 (MMP-1) production which may con-
t r i b u t et oa i r w a yi n f l a m m a t o r ya n dr e m o d e l i n gr e s p o n s e s
[27]. Finally, a clinically-proven anti-IgE monoclonal anti-
body Omalizumab abrogated the IgE-induced mediators of
asthma relevance such as IL-4, IL-6, IL-8, and TNF [12].
The current study extends the function of IgE on HASM
cells by suggesting a direct mitogenic effect which may
have critical consequences on airway tissue remodeling.
Interestingly, IgE induced significantly higher cell prolifera-
tion in ASM cells obtained from asthma compared to that
from normal individuals [16]. In vivo, anti-IgE treatment
decreased the thickness of ASM layer compared with the
ovalbumin (OVA)-challenged mice [28], suggesting that
IgE could be one of the factors inducing ASM remodeling
in vivo. Although the low affinity (FcεRII/CD23) receptor
has also been described in ASM cells with enhanced signal
in ASM tissue from asthma [29], and Roth et al. have sug-
gested the involvement of both FcεRII/CD23 and FcεRI in
IgE-induced ASM remodeling [16]; presently observed
proliferative effect of IgE appear to primarily involve FcεRI
since the lentiviral shRNA-mediated inhibition of spleen
tyrosine kinase (Syk), a signature kinase in FcεRI signaling
[22], abolished the IgE-induced HASM proliferation.
Figure 4 MAPK and Akt inhibitors abrogate the IgE-induced HASM cell proliferation.
3H-thymidine incorporation assay was performed in
serum-starved HASM cells stimulated with IgE for 24 h following pretreatment for 1 h with inhibitors of ERK 1/2 (1 μM, U0126), JNK (10 nM,
SP600125), and p38 MAPK (10 μM, SB203580), and Akt (10 μM, TAT-Akt-in). #p< 0.05, ##p<0.01 compared with unstimulated control. *p<0.05,
**p< 0.01, ns, non-significant compared with IgE-stimulated cells.
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crease in basal ASM cell proliferation. Previous studies
have shown that Syk regulates proliferation and migration
in non hematopoietic cells. In Syk knockout mice, aberrant
development of the blood and lymphatic vessels is due to
abnormal endothelial cell proliferation and migration
[30,31]. Furthermore, Syk also regulates breast epithelial
cell proliferation, migration, and differentiation. In fact, the
absence of Syk correlated with increased aggressiveness
and metastases of the tumors. In humans, ductal cell
carcinomas [32] and in vitro studies have shown that
reconstitution of Syk expression abrogated the abnormal
cell proliferation observed in a cancerous breast epithelial
cell line [33]. Therefore, the relatively higher basal cell pro-
liferation in our Syk-silenced HASM cells may be attrib-
uted to the fundamental nature of Syk in regulating the
cell proliferation.
STAT3 has been shown earlier to regulate allergic re-
sponse in asthma. Particularly, epithelial STAT3 was
identified as a critical regulator of allergen-induced
inflammation and AHR in a murine model of asthma
[34], IL-17A-induced STAT3 activation led to CCL11/
eotaxin-1 production in HASM [21], and PDGF-induced
Figure 5 Lentivirus-mediated STAT3-inhibition abrogates IgE- and PDGF-induced proliferation in HASM cells. (A) IgE-induced STAT3
phosphorylation was determined by Western blotting. (B) Summary of four experiments to assess IgE-induced STAT3 phosphorylation. (C)
Expression of total STAT3 in wild-type (WT or non-transduced), scramble-shRNA, and STAT3-shRNA–transduced HASM cells was analyzed by
Western blotting. (D) Stably lentivirus-transduced HASM cells were stimulated with IgE, PDGF-BB, or 10% FBS, and
3H-thymidine incorporation
was performed. Data represents mean±SEM; *p< 0.05, ***p<0.001, ns, non-significant compared with respective unstimulated cells. ###p< 0.001
compared with STAT3-shRNA-transduced unstimulated cells.
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sides PDGF, IgE was shown to induce STAT3-dependent
transcription of pro-survival genes in mast cells [24]. We
observed a clear phosphorylation of STAT3 in response to
IgE, the functional role of which was confirmed by
lentivirus-shRNA-mediated STAT3 inhibition that com-
pletely abrogated the IgE-induced HASM cell prolifera-
tion. Interestingly, although both PDGF and IgE activated
STAT3, we did not observe any synergy between both in
modulating HASM cell proliferation (data not shown).
Although IgE-induced signaling pathways are well
characterized in inflammatory cells, there is limited in-
formation on this area in HASM cells. MAPK family is
fundamental in regulating multiple cell functions such
as cytokine expression, proliferation, and apoptosis. Al-
though Erk1/2 and p38 MAPK were shown to mediate
IgE-induced proinflammatory gene expression in HASM
recently [12], Akt was observed to be activated in re-
sponse to IgE for the first time in HASM. However, the
role of Akt (also called protein kinase B) is well defined
in HASM cell mitogenic signaling [35]. The p38 MAPK
is also known for its pro-remodeling function in allergic
asthma [36]. Furthermore, studies show that MAPK (at
least ERK1/2) can modulate the STAT3 activation in
HASM [21,37]. However, it is unclear and deserves
further investigation whether MAPK and STAT3 signal-
ing pathways cross-talk to induce IgE-mediated prolifer-
ation. Collectively, IgE induced the activation of multiple
signaling pathways (ERK1/2, p38, JNK MAPK and STAT3)
which suggests a complex network of signaling pathways
in mediating IgE-FcεR signaling in HASM cells. Further
studies are underway to delineate these cross-regulatory
interactions in HASM cell proliferation.
Mechanistically, there is sufficient evidence from past
decade to convince that the ‘IgE sensitization/mono-
meric IgE exposure’ of FcεRI on inflammatory cells itself
can activate multiple signaling pathways; induce a pleth-
ora of proinflammatory mediators release and cell sur-
vival factors, and subsequent repression of apoptosis
[38]. Interestingly, IgE-induced survival or cytokine re-
lease does not necessarily require receptor aggregation
and merely receptor occupancy can induce these effects
[39-42]. Nonetheless, the role of FcεRI cross-linking in
conferring pro-survival effect has been a matter of de-
bate. While two initial reports [39,40] suggested the lack
of cross-linking, Xiang et al. [43] argued for FcεRI cross-
linking-mediated degranulation in mast cell survival. IgE
induced monocyte survival in both instances (aggrega-
tion or no aggregation), while mast cells and asthmatic
neutrophils showed IgE-mediated survival without FcεRI
cross-linking or aggregation [3,41]. These findings are
supported by in vivo observations where IgE can pro-
mote immune sensitization to hapten in the skin, with-
out the need of antigens [44]. Not only monoclonal IgE,
a recent report suggest that the polyclonal IgE from hu-
man atopic dermatitis patients can induce survival ef-
fects and cytokine release in human cord blood-derived
mast cells, a finding that is clinically more relevant [45].
Of note, HASM cells have been shown to be activated
by both ‘sensitization alone’ [12,15,17] and ‘cross-linking’
[11,27] models. Whether the currently observed mitogenic
effects of IgE on HASM cell require cross-linking/aggre-
gation is not clear. However, the cross-linking of FcεRI-
bound IgE with anti-IgE antibodies from various sources
did not further augment the HASM cell thymidine incorp-
oration in our study (data not shown). In conclusion, our
data suggest that the mitogenic effect of IgE on HASM
cells may occur through simple receptor occupancy with-
out cross-linking.
Omalizumab, the clinically approved anti-IgE antibody
blocks the interaction of IgE with FcεRI and has shown
clinical benefits in controlling allergic inflammation, and
offered improvement in asthma symptoms, reduced fre-
quency of asthma exacerbations, and significantly lowered
the use of inhaled corticosteroids [46,47]. Finally, the pro-
posal that IgE can induce ASM remodeling is bolstered by
two recent clinical studies wherein clinical anti-IgE anti-
body treatment significantly reduced the airway wall thick-
ness and airway inflammation in severe allergic asthma
[16,48,49]. Importantly, anti-IgE therapy may not be the
best approach for clinical benefit since IgE already bound
to mast cells and basophils and residual IgE can still trig-
ger cell activation. Blocking the FcεRI may be a theoretic-
ally better approach. Recent studies have showed that a
novel FcεRI-mimetic peptide E (PepE) can block IgE bind-
ing to FcεRI and can prevent anaphylaxis in WT mice but
has no capacity of blocking anaphylaxis in IgE KO mice
that was given IgE before treatment [50]. This suggests
that PepE can block the binding of free IgE to FcεRI but
cannot compete with the receptor for already bound IgE
in vivo. In conclusion, blocking the IgE-FcεR interaction,
not only on inflammatory cells but also on the airway
structural (HASM) cells should be considered as a novel
tool to inhibit allergic sensitization-mediated airway re-
modeling in asthma.
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